A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma
NCT ID: NCT00551252
Last Updated: 2007-10-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
56 participants
INTERVENTIONAL
2008-01-31
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PURPOSE Primary objective of the phase II
\> Efficacy, i.e., response rate to study drugs
Secondary objectives of the phase II
* Duration of response
* Time to progression
* Toxicity profile
* Overall survival
PRIMARY VARIABLE The primary efficacy variable for the phase II part of the study is Best Overall Tumor Response, evaluated using the "Modified RECIST criteria for assessment of response in malignant pleural mesothelioma"
SECONDARY VARIABLES
* Progression-free survival (PFS) form 1st administration onwards
* Overall survival
* Safety criteria, according to NCI-CTC criteria version 3.0
EFFICACY Objective tumor response assesed using the "Modified RECIST criteria for assessment of response in malignant pleural mesothelioma" SAFETY
* Adverse events
* Vital signs
* Clinical and biohumoral findings
TREATMENT SCHEDULE
* Gemzar 500 mg/m2, i.v., days 1 and 8 of a 21-days schedule, plus
* Glivec 400 mg/die., per os
STATISTICAL DESIGN The study follows a two-stage design, according to the Simon model. We assume that with a response rate of 5% (H0) or less the drug is likely to be ineffective, and also, that, for the drug to be effective, a target response rate of 15% (H1) is required. With a probability errors alfa of 5% and beta 20%, the calculated sample size is as reported in "PLANNED NUMBER OF PTS."
PLANNED NUMBER OF PTS. 23 or 56 patients, evaluable for efficacy. The number depends on the response rate. When 2 or more objective responses, i.e., CR or PR, are observed in the first 23 patients, the total number of patients will be increased to 56, otherwise the study will be stopped
STATISTICAL EVALUATION Efficacy and safety variables will be evaluated descriptively. Indeed, ORR estimates and its exact 95% confidence interval will be calculated. Kaplan-Meier method will be used to estimate duration of response, PFS and OS
DURATION OF TREATMENT All patients are scheduled to receive at least two cycles of chemotherapy unless there is unacceptable toxicity, progressive disease, or the patient requires or asks for withdrawal from the study Responding patients will receive treatment for 6 cycles or earlier if progression or unbearable toxicity Disease status will be re-evaluated every two cycles, using the same imaging procedures used at baseline, i.e., CT or NMR
INCLUSION CRITERIA
* Age of \> 18 years and \< 72 years
* Patients with a histologically proven malignant mesothelioma of the pleura or of the peritoneum, expressing either PDFGR-beta or C-Kit by immunochemistry (ICH)
* Locally advanced disease, unsuitable for curative surgical resection, or metastatic disease
* Confirmed progression of the disease according to modified REcist-criteria, documented after a first-line, systemic (premetrex+cisplatin regimen) or local treatment (i.e., intrapleuric)
* ECOG Performance Status of 0, 1 or 2
* Life expectancy of at least 3 months
* Capability of understanding the objectives of the study and giving written informed consent
* Willingness and ability to comply with study requirements
* Sufficient caloric and fluid intake, including patients under enteral or parenteral nutrition
EXCLUSION CRITERIA
* Co-existing tumors of different histologic origin, except non melanomatous localized skin cancer and/or in situ cervical carcinoma
* A history of earlier tumors of different histologic origin being in complete remission since less than 5 years
* Unresolved toxicity from prior antitumor treatment(s)
* Primary peritoneal mesothelioma
* Any of the following abnormal baseline hematological values:
* Hb \< 9 g/dL
* WBC \< 3 x 109/L
* Neutrophils \< 1.5 x 109/L
* Platelets \< 100 x 109/L
* Serum bilirubin \> 2.5 mg/dL
* ALAT and ASAT \> 3 x UNL (unless due to liver metastases)
* Serum creatinine \> 1.5 mg/dL
* Clinically relevant cardiovascular disease, i.e., myocardial infarction or other severe coronary artery diseases within the prior 6 months, cardiac arrythmia requiring medication, uncontrolled hypertension, overt cardiac failure or non compensated chronic heart disease in NYHA class II or more
* History of psychiatric disabilities, potentially interfering with the capability of giving adequate informed consent
* Pregnant or lactating women or inability/unwillingness to practice a medically approved method of contraception during study period (including 3 months following the end of treatment)
* Uncontrolled active infections
* Any condition which, in the judgement of the Investigator, would place the patient at undue risk or interfere with the results of the study
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
I
Imatinib mesylate plus Gemcitabine
Imatinib (400 mg daily) + Gemcitabine (500 mg/sqm, days 1 and 8 every 21 days) for a maximum of 6 cycles
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Imatinib mesylate plus Gemcitabine
Imatinib (400 mg daily) + Gemcitabine (500 mg/sqm, days 1 and 8 every 21 days) for a maximum of 6 cycles
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with a histologically proven malignant mesothelioma of the pleura or of the peritoneum, expressing either PDFGR-beta or C-Kit by immunochemistry (ICH)
* Locally advanced disease, unsuitable for curative surgical resection, or metastatic disease
* Confirmed progression of the disease according to modified REcist-criteria, documented after a first-line, systemic (premetrex+cisplatin regimen) or local treatment (i.e., intrapleuric)
* ECOG Performance Status of 0, 1 or 2
* Life expectancy of at least 3 months
* Capability of understanding the objectives of the study and giving written informed consent
* Willingness and ability to comply with study requirements
* Sufficient caloric and fluid intake, including patients under enteral or parenteral nutrition
Exclusion Criteria
* A history of earlier tumors of different histologic origin being in complete remission since less than 5 years
* Unresolved toxicity from prior antitumor treatment(s)
* Primary peritoneal mesothelioma
* Any of the following abnormal baseline hematological values:
* Hb \< 9 g/dL
* WBC \< 3 x 109/L
* Neutrophils \< 1.5 x 109/L
* Platelets \< 100 x 109/L
* Serum bilirubin \> 2.5 mg/dL
* ALAT and ASAT \> 3 x UNL (unless due to liver metastases)
* Serum creatinine \> 1.5 mg/dL
* Clinically relevant cardiovascular disease, i.e., myocardial infarction or other severe coronary artery diseases within the prior 6 months, cardiac arrythmia requiring medication, uncontrolled hypertension, overt cardiac failure or non compensated chronic heart disease in NYHA class II or more
* History of psychiatric disabilities, potentially interfering with the capability of giving adequate informed consent
* Pregnant or lactating women or inability/unwillingness to practice a medically approved method of contraception during study period (including 3 months following the end of treatment)
* Uncontrolled active infections
* Any condition which, in the judgement of the Investigator, would place the patient at undue risk or interfere with the results of the study
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gruppo Italiano MEsotelioma
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Camillo Porta, MD
Role: PRINCIPAL_INVESTIGATOR
Medical Oncology, IRCCS San Matteo University Hospital Foundation, pavia, Italy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical Oncology, IRCCS San Matteo University Hospital Foundation
Pavia, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Bertino P, Porta C, Barbone D, Germano S, Busacca S, Pinato S, Tassi G, Favoni R, Gaudino G, Mutti L. Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax. 2007 Aug;62(8):690-5. doi: 10.1136/thx.2006.069872. Epub 2007 Feb 20.
Related Links
Access external resources that provide additional context or updates about the study.
Italian Mesothelioma Group Homepage
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GIMe/01/06
Identifier Type: -
Identifier Source: org_study_id